Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced positive results...
Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...
Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus
Beijing-based biotech company Huahui Health, specializing in viral hepatitis, hepatology, and oncology, has announced that...
Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
Holland-based Xeltis AG has announced the enrollment of the first patient in a US-staged pivotal...
Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful...
Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
NMPA’s CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...
Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered...
Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer
US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with...
Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...
Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...
Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China
China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...
VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC
Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced...
Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...
Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336
Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...
CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...
NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology
China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...